$MTNB News

Last published 1mo ago

1mo agoMTNBGH Power Signs Multi-Year Hydrogen Offtake Agreement with Change Energy for Hamilton Facility OutputGlobeNewswireToronto, Canada, Sept. 14, 2026 (GLOBE NEWSWIRE) -- GH Power Inc. ("GH Power" or the "Company") (NYSE:MTNB), a Canadian clean energy and critical materials technology company, today announced that it
2mo agoMTNBMatinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing StandardsGlobeNewswireBEDMINSTER, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the "Company") (NYSE:MTNB) announced today that on August 31, 2026, it received a notice (the "Notice") from the
3mo agoMTNBGH Power and TKMS Continue to Explore Clean Energy Collaboration in Support of Canada’s Future Patrol Submarine ProjectBusiness WireGH Power Inc. ("GH Power"), a Canadian clean energy and critical materials technology company, today confirmed that the Government of Canada has selected TKMS, one of the world's leading naval shipbuilders
4mo agoMTNBGH Power, the Pioneering Clean Energy and Critical Materials Company, to Go Public through Business Combination with Matinas BioPharmaBusiness WireFollowing the transaction, the new public company will focus its efforts on the continued development and scale-up of GH Power’s technology platform, expanding project development activities in North America and
4mo agoMTNBMatinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity PharmaceuticalsGlobeNewswireWill create publicly traded advanced clean energy company focused on modular carbon-free energy, green hydrogen, critical materials and industrial decarbonization Business Combination expected to provide public market
4mo agoMTNBMatinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain ComplianceGlobeNewswireBEDMINSTER, N.J., June 26, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the "Company") (NYSE:MTNB) announced today that on June 24, 2026, it received a notice (the "Notice") from the NYSE
7mo agoMTNBMatinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing StandardsGlobeNewswireBEDMINSTER, N.J., April 03, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the "Company") (NYSE:MTNB) announced today that on April 2, 2026, it received a notice (the "Notice") from the NYSE American LLC
1y agoGRCE MTNB ONVOMatinas BioPharma Appoints Seasoned Biotech Leaders to Board of DirectorsGlobeNewswireBEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of
1y agoMTNBMatinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of DirectorsGlobeNewswireBEDMINSTER, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) (the "Company") today announced that the Company entered into a securities purchase agreement (the "Agreement") with a
1y agoMTNBMatinas BioPharma Appoints Evelyn D'An to Board of Directors as Audit Committee ChairGlobeNewswireBEDMINSTER, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of Evelyn D'An to its Board of Directors as an independent director and Chair of the
1y agoMTNBMatinas BioPharma Receives NYSE Noncompliance NoticeGlobeNewswireBEDMINSTER, N.J. , Jan. 10, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) announces that on January 6, 2025, it received a NYSE American LLC notice indicating that the Company has fallen below
2y agoMTNBMatinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce ReductionGlobeNewswireBEDMINSTER, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) announces that negotiations under the previously disclosed non-binding term sheet regarding global rights to MAT2203, its
2y agoMTNBMatinas BioPharma Holdings, Inc. (MTNB) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoMTNBMatinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business UpdateGlobeNewswireSigns non-binding term sheet granting global rights to develop and commercialize oral MAT2203 for invasive aspergillosis and potentially other invasive fungal infections 31 patients have enrolled in the MAT2203
2y agoMTNBMatinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024GlobeNewswireBEDMINSTER, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal
2y agoMTNBMatinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access ProgramGlobeNewswireBEDMINSTER, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal
2y agoMTNBMatinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. PerlinGlobeNewswireBEDMINSTER, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal
2y agoMTNBNew In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024GlobeNewswireBEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal
2y agoMTNBMatinas BioPharma Holdings, Inc. (MTNB) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoMTNBMatinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business UpdateGlobeNewswireRecent $10 million financing expected to fund planned development programs and operations into the second quarter of 2025 Discussions to secure a partner to advance MAT2203 into the Phase 3 ORALTO trial remain on track
2y agoMTNBMatinas BioPharma's LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual MeetingGlobeNewswireBEDMINSTER, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal
2y agoMTNBMatinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024GlobeNewswireBEDMINSTER, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal
2y agoMTNBIn Vivo Efficacy of Matinas BioPharma's Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and ChemotherapyGlobeNewswireBEDMINSTER, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal
2y agoMTNBMatinas BioPharma Prices $10 Million Registered Direct OfferingGlobeNewswireBEDMINSTER, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) ("Matinas BioPharma" or the "Company"), a clinical-stage biopharmaceutical company focused on delivering groundbreaking
2y agoMTNBMatinas BioPharma Holdings, Inc. (MTNB) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts
2y agoMTNBMatinas BioPharma Reports 2023 Financial Results and Provides a Business UpdateGlobeNewswireClear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions Continued success of Compassionate/Expanded Use Access Program
2y agoMTNBMatinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel FormulationGlobeNewswireDaily oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of weight loss, compared to an average peak weight loss of 20% with IV-docetaxel Results build on data
2y agoMTNBThree Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical ResponseGlobeNewswireBEDMINSTER, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal
2y agoMTNBMatinas BioPharma Regains Compliance with NYSE American Continued Listing StandardsGlobeNewswireBEDMINSTER, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal
2y agoMTNBMatinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical ResolutionGlobeNewswireA total of 19 patients with serious/life-threatening invasive fungal infections have been enrolled, including aspergillosis, mucormycosis, fusarium, candidiasis, cryptococcosis, and endemic mycoses such as
2y agoMTNBMatinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive AspergillosisGlobeNewswireORALTO Phase 3 trial focused on desired initial target indication of early oral step-down treatment of invasive aspergillosis infections in adults who have limited or no treatment options Non-inferiority trial will
2y agoMTNBMatinas BioPharma to Present at Biotech Showcase 2024GlobeNewswireBEDMINSTER, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small molecules and small
2y agoMTNBMatinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small OligonucleotidesGlobeNewswireIn an acute colitis model, data show statistically significant knockdown of elevated levels of serum TNFα, reductions in tissue TNFα mRNA and improvement in disease activity scores In an acute psoriasis model, data
2y agoMTNBMatinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDAGlobeNewswireWritten Preliminary Comments on the Phase 3 Registration Trial for MAT2203 Move Company Closer to Full Alignment with FDA Matinas to Meet with FDA Early in the First Quarter of 2024 to Finalize Phase 3 Study Design
3y agoMTNBMatinas BioPharma Reports Third Quarter 2023 Financial Results and Provides a Business UpdateGlobeNewswireFDA feedback on MAT2203 Phase 3 program supports a patient population in invasive aspergillosis with limited treatment options, acknowledges potential for LPAD pathway; composite superiority endpoint under evaluation to
3y agoMTNBMatinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma ModelGlobeNewswireBEDMINSTER, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal
3y agoMTNBMatinas BioPharma to Webcast Conference Call to Discuss Third Quarter 2023 Financial Results and Provide a Business Update on November 8, 2023GlobeNewswireBEDMINSTER, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small
3y agoMTNBPatient with Candida krusei Infection in Matinas BioPharma's Oral MAT2203 Expanded Access Program Achieves Complete Clinical ResolutionGlobeNewswireBEDMINSTER, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform
3y agoMTNBMatinas BioPharma to Present at Two Investment Conferences in October 2023GlobeNewswireBEDMINSTER, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small molecules and small
3y agoMTNBMatinas BioPharma to Feature MAT2203 in a Pipeline Presentation at IDWeekGlobeNewswireBEDMINSTER, N.J., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small molecules and small
3y agoMTNBMatinas BioPharma Announces Notification of NYSE American Continued Listing DeficiencyGlobeNewswireBEDMINSTER, N.J., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small molecules and small
3y agoMTNBMatinas BioPharma to Participate in the H.C. Wainwright Global Investment ConferenceGlobeNewswireBEDMINSTER, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small
3y agoMTNBMatinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious DiseasesGlobeNewswireBEDMINSTER, N.J., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform
3y agoMTNBMatinas BioPharma to Participate in the BTIG Virtual Biotechnology Conference 2023GlobeNewswireBEDMINSTER, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small
3y agoMTNBMatinas BioPharma to Present at the JMP Securities Life Sciences Conference on May 15, 2023GlobeNewswireBEDMINSTER, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform
3y agoMTNBMatinas BioPharma Reports First Quarter 2023 Financial Results and Provides a Business UpdateGlobeNewswireFDA feedback from Type B meeting reiterated the Agency's intent to work collaboratively in advancing development of MAT2203 for the treatment of invasive fungal infections (IFIs) Phase 3 trial design is being finalized
3y agoMTNBMatinas BioPharma to Webcast Conference Call to Discuss First Quarter 2023 Financial Results and Provide a Business Update on May 10, 2023GlobeNewswireBEDMINSTER, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small
3y agoMTNBCompassionate Use Patient Treated with Matinas BioPharma's MAT2203 and Showing Complete Clinical Resolution of Rare R. mucilaginosa Fungal Infection Featured in Oral Presentation at ECCMIDGlobeNewswireBEDMINSTER, N.J., April 18, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform
3y agoMTNBMatinas BioPharma Reports 2022 Financial Results and Provides a Business UpdateGlobeNewswireNear-term data readouts from internal and collaborative programs expected to support advancement of the LNC platform for delivery of nucleic acids FDA feedback from MAT2203 Type B meeting expected to impact
3y agoMTNBMatinas BioPharma to Webcast Conference Call to Discuss 2022 Financial Results and Provide a Business Update on March 15, 2023GlobeNewswireBEDMINSTER, N.J., March 08, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small